Cetuximab, an IgG1 chimeric monoclonal antibody targeting EGFR, was one of the first-line treatments for RM HNSCC patients with low programmed death ligand 1 (PD-L1) expression (Burtness et al., 2019; Vermorken et al., 2008). Here, EGFR is linked to head and neck squamous cell carcinoma.